IPO
IPO filing, visualized

NuvOx Therapeutics, Inc.

Oxygen-delivery drug for diseases caused by low oxygen

NUOX · NYSE AmericanS-1/A · Oct 29, 2026Price range set

Pricing expected any day (our estimate) · latest SEC filing Oct 29, 2026.

Pinch-zoom for details.

The offering

Price range
$6–$8
per share
Shares offered
2.86M
sold by the company
Raise at $7 midpoint
$20.0M
2,860,000 × $7, before fees
Net proceeds (company est.)
$17.4M
at $7 a share

What the company does

NuvOx Therapeutics is a clinical-stage drug developer. Its candidate, NanO2, is an intravenous emulsion that turns to gas at body temperature to carry more oxygen to tissues, for diseases where lack of oxygen plays a critical role.

Revenue

Fiscal year

1st 9 months

Operating result

Fiscal year

1st 9 months

Net result

Fiscal year

1st 9 months

Cash before and after the IPO

Cash and equivalents on the latest balance sheet, actual and as adjusted for the offering, as shown in the filing.

Things to weigh

  • Loss-making: net loss of $7.00M in 9M 2026.

The numbers

$FY2024FY2025YoY9M 20259M 2026Change
Revenue512K980K+91.4%876K856K−2.3%
Operating result(4.82M)(5.10M)−5.9%(3.85M)(3.60M)+6.5%
Net result(6.64M)(16.6M)−150%(13.6M)(7.00M)+48.3%
$FY2024FY2025YoY
Revenue512K980K+91.4%
Operating result(4.82M)(5.10M)−5.9%
Net result(6.64M)(16.6M)−150%
$9M 20259M 2026Change
Revenue876K856K−2.3%
Operating result(3.85M)(3.60M)+6.5%
Net result(13.6M)(7.00M)+48.3%

Values as filed, shortened (K = thousand, M = million, B = billion); losses in parentheses. Change columns compare each period with the same period a year earlier; a bigger loss shows as a negative change. Green is better for the company, red worse; n/m where the sign flips.

Risks

  1. Development-stage with a short operating history.
  2. No approved products yet.
  3. Has lost money and expects more losses.
  4. Its auditor has substantial doubt that it can keep operating.
  5. The IPO money will only last a limited time.

In plain English, from the filing's risk factors.

Strategy

The filing doesn't set out its strategy in a list we could read.

Source: NuvOx Therapeutics, Inc.'s Form S-1/A, filed with the SEC on Oct 29, 2026 (preliminary prospectus). Figures are as filed; changes are worked out from them. Not investment advice.

10KDecoder10KDecoder.com

10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.